Accessibility:
Text size
Wed. Nov 18th, 2026
University Hall at the University of Toledo, a stone collegiate building with a tower, lawns and walkways in frontUniversity Hall at the University of Toledo in Toledo, Ohio. Photo: MrJacon000, CC BY-SA

Two University of Toledo scientists are exploring a new category of drug aimed at drug-resistant fungal infections, targeting the fungal genus Candida with support from the National Institutes of Health (NIH), the University of Toledo announced on November 18, 2026.

Dr. Heather Conti and Dr. Ronald Viola, of the College of Natural Sciences and Mathematics, are collaborating on the work, which is supported by more than $215,000 from the National Institute of Allergy and Infectious Diseases under a two-year grant, UToledo News reported.

Their approach uses covalent drugs, which work by binding irreversibly to a targeted molecule — in this case, an essential enzyme in Candida — instead of relying on the weaker, non-covalent bonds that other drug categories use to identify and inhibit a target, UToledo News reported.

Because that mechanism is fundamentally different from the drugs now prescribed for fungal infections, covalent drugs are especially promising as alternatives to medications that are losing effectiveness against drug-resistant strains, UToledo News reported.

Conti’s laboratory specializes in how the body fights Candida albicans, the species responsible for the oral infection commonly known as thrush. Viola, a Distinguished University Professor emeritus in the Department of Chemistry and Biochemistry, brings expertise in enzyme-catalyzed reactions and an established body of research into the essential Candida enzyme at the center of the project, UToledo News reported.

Working with a postdoctoral researcher in Wolfe Hall, Conti and Viola will explore and optimize a class of compounds they have identified to develop more potent enzyme inactivators, UToledo News reported.

The project pairs two kinds of expertise that rarely sit in the same laboratory. Conti studies the immune side — how the body recognizes and fights Candida albicans — while Viola studies the chemistry of the enzyme the fungus cannot live without. A covalent drug is designed to lock onto that enzyme permanently, so the enzyme is inactivated rather than temporarily blocked, UToledo News reported.

Fungal infections from Candida can range from superficial to deadly serious, and the university said the research could significantly improve the outlook for patients whose infections no longer respond to standard treatment. The work is also meant to lay the foundation for eventual drugs that could save the lives of patients fighting drug-resistant fungal infections, UToledo News reported.

By Maria Hartman

Maria Hartman covers health and the stories that land on Ohio families — hospitals, care access, and the kitchen-table issues in between. She will also lead NewsForce247's lifestyle coverage.

Leave a Reply

Your email address will not be published. Required fields are marked *